Octapharma USA Inc.
Paramus, NJ
- UEI
- FKJKNJVR1HV4
- CAGE
- 484Y2
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 117 W Century Rd, Paramus, NJ 07652, USA
- Website
- octapharmausa.com
- Founded
- 1983
- Employees
- 1K-5K
- Estimated annual revenue
- $500M-$1B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Purchase of 1,500 octaplaslg units for the united states marine corp | Defense Health Agency | $1,800,000 | |
| 1,600 units of octaplaslg delivered to blood bank west | Defense Health Agency | $1,920,000 | |
| Third task order for the purchase of octaplaslg for program executive office - operational medicine | Defense Health Agency | $1,800,000 | |
| First task order for the purchase of octaplaslg for program executive office - operational medicine. | Defense Health Agency | $2,000,000 | |
| This supply purchase is for 1,600 units of octaplaslg kits | Defense Health Agency | $1,600,000 |
About Octapharma USA Inc.
Octapharma USA Inc., a foreign-owned pharmaceutical manufacturer based in Paramus, New Jersey, supplies blood plasma products and ancillary medical supplies to the Defense Health Agency and Department of Veterans Affairs as a prime contractor with no subcontract footprint. The company competes full-and-open with no small business set-asides across its federal work and is registered as a federal contractor since 2005.
Octapharma's federal capability centers on Octaplas LG, a solvent/detergent-treated liquid plasma product authorized under Food and Drug Administration Emergency Use Authorization, sold alongside sterile water for injection, transfusion sets with filters, transfer sets, alcohol swabs, and vented spike adapters for blood type AB. The company holds a single-award Indefinite Delivery Contract with the Defense Health Agency, valued at $14.88 million with ultimate completion on September 14, 2030, from which five task orders totaling $9.1 million have been issued. Representative delivery orders include a $1.92 million order (January 16, 2026) for 1,600 units of Octaplas LG to Blood Bank West, a $1.8 million order (March 6, 2026) for 1,500 units supporting the United States Marine Corps with performance at Frederick, Maryland, and a $2 million order (September 16, 2025) supporting the Program Executive Office for Operational Medicine performed at Travis Air Force Base, California. The company also fulfills orders from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 (three awards, $15.3 million combined potential value) and carries a small order from the White House Medical Unit ($100,000, completed June 8, 2025).
Customer concentration is acute: the Defense Health Agency accounts for six awards and $22.1 million of the $39.4 million combined potential value across twelve total awards, representing 100% of customer coverage when the VA networks are included. Activity has surged from one award in 2020 to five in 2025 and two in early 2026, driven by military medical readiness demand for blood products supporting combat casualty care and coagulopathy treatment. Eleven awards (combined potential value $24.4 million) are either complete or reach ultimate completion by July 3, 2026, creating recompete exposure concentrated in the Defense Health Agency renewal of its master contract. Octapharma operates across NAICS 325412 (Biological Product Manufacturing) and 325412 (Pharmaceutical Preparation Manufacturing), with PSC coding reflecting Drugs and Biologicals (6 awards) and Medical and Surgical Instruments and Equipment (6 awards). The vendor obligated $9.2 million of its $39.4 million potential value to date, indicating front-loaded performance on near-term delivery orders against the Defense Health Agency master contract.
Contract vehicles
Quick answers
What is Octapharma USA Inc.'s UEI?
Octapharma USA Inc.'s Unique Entity ID (UEI) in SAM.gov is FKJKNJVR1HV4.
What is Octapharma USA Inc.'s CAGE code?
Octapharma USA Inc.'s CAGE code is 484Y2.
What is Octapharma USA Inc.'s primary NAICS code?
Octapharma USA Inc.'s primary NAICS code is 325414 (Biological Product (except Diagnostic) Manufacturing).
Where is Octapharma USA Inc. located?
Octapharma USA Inc.'s physical address in SAM.gov is 117 W Century Rd, Paramus, NJ 07652, USA.
Is Octapharma USA Inc. registered in SAM.gov?
Yes. Octapharma USA Inc.'s SAM.gov registration is active through August 4, 2027.
Which contract vehicles does Octapharma USA Inc. hold?
Octapharma USA Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Octapharma USA Inc.'s most recent federal award?
Octapharma USA Inc.'s most recent federal contract award is Purchase of 1,500 octaplaslg units for the united states marine corp (HT942726FE025), from Defense Health Agency, on March 6, 2026.
On GovTribe
See Octapharma USA Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors